Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

PURPOSE: Despite significant therapeutic progress in multiple myeloma, drug resistance is uniformly inevitable and new treatments are needed. Our aim was to identify novel, efficacious small-molecule combinations for use in drug resistant multiple myeloma. EXPERIMENTAL DESIGN: A panel of 116 small m...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2015
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4662464/
https://ncbi.nlm.nih.gov/pubmed/26254279
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы